Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Company profile from EODHD, stored Nov 4, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Nov 2, 2026 | $127.3M | +30.2% | 94.1% | $71.1M | $63.1M |
| Jun 2026filed Aug 3, 2026 | $119.2M | +24.1% | 94.6% | $58.4M | $54.8M |
| Mar 2026filed May 4, 2026 | $116.4M | +31.9% | 94.6% | $53.7M | $55.9M |
| Dec 2025filed Feb 17, 2026 | $107.1M | +17.5% | 89.8% | $44.4M | $51.4M |
| Sep 2025filed Nov 3, 2025 | $97.8M | +16.6% | 94.2% | $41.4M | $79.4M |
| Jun 2025filed Aug 4, 2025 | $96.0M | +36.6% | 92.5% | $39.3M | $38.3M |
| Mar 2025filed May 6, 2025 | $88.2M | +94.9% | 94.3% | $36.2M | $35.7M |
| Dec 2024filed Feb 19, 2025 | $91.1M | +116.3% | 94.6% | $41.4M | $45.5M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 17, 2026 | $389.1M | +33.9% | 92.6% | $161.3M | $204.8M |
| Dec 2024filed Feb 19, 2025 | $290.5M | +473.0% | 93.1% | $65.7M | $89.2M |
| Dec 2023filed Feb 26, 2024 | $50.7M | — | 93.9% | -$109.7M | $10.9M |
| Dec 2022filed Feb 27, 2023 | — | — | — | -$145.2M | -$140.0M |
| Dec 2021filed Feb 28, 2022 | — | — | — | -$68.3M | -$69.6M |
| Dec 2020filed Mar 1, 2021 | — | — | — | -$33.0M | -$32.2M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched KRYS. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
2,936,047 shares short
-539,480 shares (-15.5%) vs Sep 30, 2026
12.4% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
3,475,527 shares short
+311,885 shares (+9.9%) vs Sep 15, 2026
14.7% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
3,163,642 shares short
-184,171 shares (-5.5%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
3,347,813 shares short
+142,904 shares (+4.5%) vs Aug 14, 2026
14.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
3,204,909 shares short
+2,649 shares (+0.1%) vs Jul 31, 2026
13.7% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
3,202,260 shares short
-294,388 shares (-8.4%) vs Jul 15, 2026
13.7% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind KRYS’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if KRYS is in your portfolio and how much it contributes.
Sign inLoading market dates
61 smart-money holders: institutions with a high Holder IQ
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 64 days ago
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
423 filers reported a long position in KRYS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
61.9%
of the 30.3M shares 13-F filers reported
Moves vs Q1 2026
7 added2 trimmed
1 unchanged
Net shares held
+2.8%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $1.6B · 4.4M shares | 4.4M | +1% |
| 2 | BlackRock, Inc. | $1.6B · 4.2M shares | 4.2M | +6.1% |
| 3 | Avoro Capital Advisors LLC | $1.1B · 2.9M shares | 2.9M | Unchanged |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | $585.3M · 1.6M shares | 1.6M | +8.1% |
| 5 | STATE STREET CORP | $502.2M · 1.4M shares | 1.4M | +2.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $461.1M · 1.2M shares | 1.2M | +6.5% |
| 7 | Soleus Capital Management, L.P. | $349.1M · 939.3K shares | 939.3K | -18.5% |
| 8 | Capital World Investors | $289.1M · 777.8K shares | 777.8K | -5.7% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $259.8M · 699K shares | 699K | +8.5% |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | $255.5M · 687.4K shares | 687.4K | +41.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inHolders of more than 5% of KRYS file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 30, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive · amended | 4.43%under 5% |
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 11.6% |
| May 4, 2026 | Krishnan Krish S13G · passive · amended | 11.5% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.